{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T12:49:27Z","timestamp":1776170967215,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017055","name":"National Natural Science Foundation of China-Shandong Joint Fund","doi-asserted-by":"publisher","award":["U1906213"],"award-info":[{"award-number":["U1906213"]}],"id":[{"id":"10.13039\/100017055","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013072","name":"Major Science and Technology Project of Hainan Province","doi-asserted-by":"publisher","award":["ZDYF2021SHFZ220"],"award-info":[{"award-number":["ZDYF2021SHFZ220"]}],"id":[{"id":"10.13039\/501100013072","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21977088"],"award-info":[{"award-number":["21977088"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473838"],"award-info":[{"award-number":["82473838"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373785"],"award-info":[{"award-number":["82373785"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023MH210"],"award-info":[{"award-number":["ZR2023MH210"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejmech.2026.118760","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T17:02:13Z","timestamp":1773421333000},"page":"118760","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Novel staurosporine-type indolocarbazole glycoalkaloids as potent and selective FLT3-ITD inhibitors for acute myeloid leukemia"],"prefix":"10.1016","volume":"310","author":[{"given":"Xinxin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yating","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ni","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingxuan","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyue","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiming","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peiju","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118760_bib1","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1038\/s41375-025-02598-3","article-title":"National cancer system metrics and leukemia outcomes: an analysis of global data for pediatric and adult patients","volume":"39","author":"Wu","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2026.118760_bib2","first-page":"46","article-title":"Acute myeloid leukemia management and research in 2025","volume":"75","author":"Kantarjian","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2026.118760_bib3","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2026.118760_bib4","doi-asserted-by":"crossref","first-page":"12403","DOI":"10.1021\/acs.jmedchem.0c00696","article-title":"Small molecule Fms-like tyrosine kinase 3 inhibitors: an attractive and efficient method for the treatment of acute myeloid leukemia","volume":"63","author":"Zhong","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118760_bib5","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1021\/acs.jmedchem.0c01851","article-title":"FLT3 inhibitors in acute myeloid leukemia: challenges and recent developments in overcoming resistance","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118760_bib6","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1182\/blood.2019876821","article-title":"Availability of FLT3 inhibitors: how do we use them?","volume":"134","author":"Perl","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.118760_bib7","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1182\/blood-2013-04-493916","article-title":"G-749, a novel FLT3 kinase inhibitor can overcome drug resistance for the treatment of acute myeloid leukemia","volume":"123","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.118760_bib8","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1073\/pnas.1320661111","article-title":"Crenolanib is a selective type I pan-FLT3 inhibitor","volume":"111","author":"Smith","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2026.118760_bib9","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/cas.14274","article-title":"FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development","volume":"111","author":"Kiyoi","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2026.118760_bib10","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1021\/acs.jmedchem.0c01851","article-title":"FLT3 inhibitors in acute myeloid leukemia: challenges and recent developments in overcoming resistance","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118760_bib11","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1182\/blood-2017-05-786657","article-title":"A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations","volume":"131","author":"Yamaura","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.118760_bib12","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118760_bib13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/2040620714532123","article-title":"The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond","volume":"5","author":"Wander","year":"2014","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.ejmech.2026.118760_bib14","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1182\/blood-2005-06-2469","article-title":"Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain","volume":"107","author":"Heidel","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.118760_bib15","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/leu.2017.234","article-title":"Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial","volume":"32","author":"DeAngelo","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2026.118760_bib16","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0960-894X(01)00690-4","article-title":"Mixed lineage kinase activity of indolocarbazole analogues","volume":"12","author":"Murakata","year":"2002","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118760_bib17","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1016\/S0960-894X(03)00792-3","article-title":"Studies on cyclin-dependent kinase inhibitors: Indolo-[2,3-a]pyrrolo[3,4-c]carbazoles versus bis-indolylmaleimides","volume":"13","author":"Concha","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118760_bib18","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1016\/j.bmc.2003.09.014","article-title":"Semi-synthesis, topoisomerase I and kinases inhibitory properties, and antiproliferative activities of new rebeccamycin derivatives","volume":"11","author":"Moreau","year":"2003","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118760_bib19","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1021\/jm0493764","article-title":"Syntheses and biological activities of rebeccamycin analogues with uncommon sugars","volume":"48","author":"Zhang","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118760_bib20","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1039\/b506444a","article-title":"The synthesis of bioactive indolocarbazoles related to K-252a","volume":"3","author":"Moffat","year":"2005","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2026.118760_bib21","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.bmcl.2008.11.061","article-title":"Design and synthesis of N-methylmaleimide indolocarbazole bearing modified 2-acetamino acid moieties as topoisomerase I inhibitors","volume":"19","author":"Li","year":"2009","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.118760_bib22","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1039\/b905068j","article-title":"Generation of potent and selective kinase inhibitors by combinatorial biosynthesis of glycosylated indolocarbazoles","author":"Sanchez","year":"2009","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2026.118760_bib23","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.tet.2018.01.017","article-title":"Synthesis and antiproliferative evaluation of glucosylated pyrazole analogs of K252c","volume":"74","author":"Douara","year":"2018","journal-title":"Tetrahedron"},{"key":"10.1016\/j.ejmech.2026.118760_bib24","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-17-0530","article-title":"Inhibition of FLT3 and PIM kinases by EC-70124 exerts potent activity in preclinical models of acute myeloid leukemia","volume":"17","author":"Puente-Moncada","year":"2018","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.118760_bib25","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1021\/acsmedchemlett.0c00420","article-title":"Staurosporine analogs via C\u2212H borylation","volume":"11","author":"Gayler","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118760_bib26","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.6023\/cjoc201403046","article-title":"Synthesis and cytotoxicity of halogenated derivatives of PKC-412","volume":"34","author":"Wang","year":"2014","journal-title":"Chin. J. Org. Chem."},{"key":"10.1016\/j.ejmech.2026.118760_bib27","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1039\/D2QO00844K","article-title":"Total synthesis of indplecarkazole alkaloid ZHD-0501 and its seven isomers","volume":"9","author":"Wang","year":"2022","journal-title":"Org. Chem. Front."},{"key":"10.1016\/j.ejmech.2026.118760_bib28","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1021\/acs.jnatprod.9b00468","article-title":"Semisynthetic derivatives of fradcarbazole a and their cytotoxicity against acutemyeloid leukemia cell lines","volume":"82","author":"Li","year":"2019","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.ejmech.2026.118760_bib29","doi-asserted-by":"crossref","first-page":"7990","DOI":"10.1016\/j.tet.2015.08.065","article-title":"Biomimetic semi-synthesisof fradcarbazole A and its analogues","volume":"71","author":"Wang","year":"2015","journal-title":"Tetrahedron"},{"key":"10.1016\/j.ejmech.2026.118760_bib30","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1021\/cr800278z","article-title":"Mitsunobu and related reactions: advances and applications","volume":"109","author":"Swamy","year":"2009","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2026.118760_bib31","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1055\/s-1998-1604","article-title":"Easy microwave assisted deprotection of N-Boc derivatives","volume":"1998","author":"Siro","year":"1998","journal-title":"Synlett"},{"key":"10.1016\/j.ejmech.2026.118760_bib32","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1080\/00397910902962878","article-title":"Synthesis of arcyriarubin A and arcyriaflavin A via cross-coupling of indolylboronic acid with dibromomaleimides","volume":"40","author":"Wang","year":"2009","journal-title":"Synth. Commun."},{"key":"10.1016\/j.ejmech.2026.118760_bib33","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0968-0896(01)00013-X","article-title":"Dicaffeoyl- or digalloyl pyrrolidine and furan derivatives as HIV integrase inhibitors","volume":"9","author":"Hwang","year":"2001","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118760_bib34","doi-asserted-by":"crossref","first-page":"9791","DOI":"10.1021\/jo401512h","article-title":"Applications and limitations of the I2-mediated carbamate annulation for the synthesis of piperidines: five- versus six-membered ring formation","volume":"78","author":"Corkran","year":"2013","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2026.118760_bib35","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1021\/ol016596s","article-title":"Novel synthesis of the glycosidase inhibitor deoxymannojirimycin and of a synthetic precursor d-lyxo-Hexos-5-ulose","volume":"3","author":"O'Brien","year":"2001","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2026.118760_bib36","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1021\/acs.orglett.5b01602","article-title":"Total synthesis of the glycosylated macrolide antibiotic fidaxomicin","volume":"17","author":"Kaufmann","year":"2015","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2026.118760_bib37","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0223-5234(03)00011-4","article-title":"Rebeccamycin analogues as anti-cancer agents","volume":"38","author":"Prudhomme","year":"2003","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118760_bib38","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0163-7258(99)00005-4","article-title":"Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent","volume":"82","author":"Fabbro","year":"1999","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2026.118760_bib39","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.18632\/oncotarget.27222","article-title":"Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells","volume":"10","author":"Kawase","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2026.118760_bib40","article-title":"AutoDock vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","author":"Trott","year":"2009","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2026.118760_bib41","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","article-title":"AutoDock vina 1.2.0: new docking methods, expanded force field, and python binding","volume":"61","author":"Eberhardt","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.118760_bib42","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/pro.3235","article-title":"UCSF ChimeraX: meeting modern challenges in visualization and analysis","volume":"27","author":"Goddard","year":"2018","journal-title":"Protein Sci."},{"key":"10.1016\/j.ejmech.2026.118760_bib43","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S1535-6108(02)00069-7","article-title":"Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412","volume":"1","author":"Weisberg","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2026.118760_bib44","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1038\/sj.onc.1210980","article-title":"The FLT3 inhibitor PKC412 exerts differential cell cycle effects on leukemic cells depending on the presence of FLT3 mutations","volume":"27","author":"Odgerel","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2026.118760_bib45","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1182\/blood-2017-05-786657","article-title":"A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations","volume":"131","author":"Yamaura","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.118760_bib46","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1182\/blood-2009-01-199307","article-title":"KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR\/ABL translocation","volume":"114","author":"Shiotsu","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.118760_bib47","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1021\/acs.jmedchem.8b01594","article-title":"Discovery of N -(4-(6-Acetamidopyrimidin-4-Yloxy)Phenyl)-2-(2-(Trifluoromethyl)Phenyl)Acetamide (CHMFL-FLT3-335) as a potent FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutant selective inhibitor for acute myeloid leukemia","volume":"62","author":"Liang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118760_bib48","doi-asserted-by":"crossref","first-page":"9625","DOI":"10.1021\/acs.jmedchem.5b01611","article-title":"Discovery of (R)-1-(3-(4-Amino-3-(4-Phenoxyphenyl)-1 H-Pyrazolo[3,4- d ]Pyrimidin-1-Yl)Piperidin-1-Yl)-2-(Dimethylamino) Ethanone (CHMFL-FLT3-122) as a potent and orally available FLT3 kinase inhibitor for FLT3-ITD positive acute myeloid leukemia","volume":"58","author":"Li","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118760_bib49","doi-asserted-by":"crossref","first-page":"7955","DOI":"10.1021\/acs.jmedchem.4c03023","article-title":"Discovery of FLT3-ITD inhibitor clifutinib: a novel biphenylacetylene urea derivative in clinical trials for the treatment of relapsed\/refractory FLT3-ITD+ acute myeloid leukemia","volume":"68","author":"Liu","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118760_bib50","doi-asserted-by":"crossref","first-page":"11133","DOI":"10.1021\/acs.jmedchem.3c00575","article-title":"Inhibition of FLT3-ITD kinase in acute myeloid leukemia by new imidazo[1,2- b ]pyridazine derivatives identified by scaffold hopping","volume":"66","author":"B\u0159ehov\u00e1","year":"2023","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426002059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426002059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T11:56:39Z","timestamp":1776167799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426002059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":50,"alternative-id":["S0223523426002059"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118760","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel staurosporine-type indolocarbazole glycoalkaloids as potent and selective FLT3-ITD inhibitors for acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118760","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118760"}}